Drugs that contain Axitinib

1. Drug name - INLYTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6534524 PF PRISM CV Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
Apr, 2025

(2 years from now)

US8791140 PF PRISM CV Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals
Dec, 2030

(8 years from now)

CN101679356A PF PRISM CV Crystalline Form Of 6-[2-(Methyl-Carbamoyl)Phenylsulfanyl]-3-E-[2-(Pyridin-2- Yl)Ethenyl]Indazole Suitable For Treatment Of Abnormal Cell Growth In A Mammal
Jul, 2014

(8 years ago)

CN1495171A PF PRISM CV Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use
Jun, 2020

(2 years ago)

CN1374950A PF PRISM CV Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use
Jun, 2020

(2 years ago)

CN1234693C PF PRISM CV Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use
Jun, 2020

(2 years ago)

CN1137884C PF PRISM CV Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods Thereof
Jun, 2020

(2 years ago)

CN103626739B PF PRISM CV Suitable Treating Abnormal Cell Growing Mammal Is 6-[2-(Methyl-Carbamoyl) Phenylsulfanyl]-3-E-[2-(Pyridine--2-Yl) Ethenyl] Indazole And Crystal Form
Mar, 2028

(5 years from now)

CN103626739A PF PRISM CV Useful In The Treatment Of Abnormal Cell Growth In A Mammal Of 6 - [2 - (Methyl-Carbamyl) Phenylsulfanyl] -3-E-[2 - (Pyridin - -2 - Yl) Ethenyl] Indazole Of Crystal Form
Mar, 2028

(5 years from now)

EP1614683A1 PF PRISM CV Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use
Jun, 2020

(2 years ago)

EP1614683B1 PF PRISM CV Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use
Jun, 2020

(2 years ago)

EP1218348A2 PF PRISM CV Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use
Jun, 2025

(2 years from now)

EP1218348B1 PF PRISM CV Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use
Jun, 2025

(2 years from now)

EP3252047A2 PF PRISM CV Crystalline Forms Of 6-[2-(Methylcarbamoyl)Phenylsulfanyl]-3-E-[2-(Pyridin-2-Yl)Ethenyl]Indazole Suitable For The Treatment Of Abnormal Cell Growth In Mammals
Mar, 2028

(5 years from now)

EP3252047A3 PF PRISM CV Crystalline Forms Of 6-[2-(Methylcarbamoyl)Phenylsulfanyl]-3-E-[2-(Pyridin-2-Yl)Ethenyl]Indazole Suitable For The Treatment Of Abnormal Cell Growth In Mammals
Mar, 2028

(5 years from now)

EP2134702B1 PF PRISM CV Crystalline Forms Of 6-[2-(Methylcarbamoyl)Phenylsulfanyl]-3-E-[2-(Pyridin-2-Yl)Ethenyl]Indazole Suitable For The Treatment Of Abnormal Cell Growth In Mammals
Mar, 2028

(5 years from now)

EP2134702A2 PF PRISM CV Crystalline Forms Of 6-[2-(Methylcarbamoyl)Phenylsulfanyl]-3-E-[2-(Pyridin-2-Yl)Ethenyl]Indazole Suitable For The Treatment Of Abnormal Cell Growth In Mammals
Mar, 2028

(5 years from now)

EP3252047B1 PF PRISM CV Crystalline Forms Of 6-[2-(Methylcarbamoyl)Phenylsulfanyl]-3-E-[2-(Pyridin-2-Yl)Ethenyl]Indazole Suitable For The Treatment Of Abnormal Cell Growth In Mammals
Mar, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10570202 PF PRISM CV Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer Feb, 2035

(12 years from now)

US10869924 PF PRISM CV PD-L1 antagonist combination treatments Nov, 2036

(14 years from now)

Treatment: In combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma; Axitinib in combination with avelumab for the first-line treatment of patients with advanced renal cell carcinoma

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
1MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.